Anti-Migraine Drugs That Block CGRP Also Reduce Heart Contraction Force in Human Tissue

Ex vivo study using isolated, electrically driven human atrial tissue preparations obtained from adult patients during open-heart surgery. CGRP was applied at increasing concentrations (1-100 nM) to measure its effect on force of contraction. Three anti-migraine drugs were then tested for their ability to block CGRP's cardiac effects, both as pre-treatment and as post-treatment. The PDE III inhibitor cilostamide was used to enhance CGRP's effects in some experiments.

Millions of people take CGRP-targeting migraine drugs (like Aimovig/erenumab, Vyepti/eptinezumab, and Ubrelvy/ubrogepant). CGRP is present not just in the brain but in the heart, where it affects contraction force. This study is the first to show that therapeutic concentrations of these migraine drugs block CGRP's cardiac effects in human atrial tissue — raising questions about potential cardiovascular consequences of long-term CGRP inhibition.

CGRP-targeting therapies revolutionized migraine treatment and are now used by millions globally. But CGRP has roles throughout the body — in blood vessels, the heart, the gut, and wound healing. This study adds to growing questions about the systemic consequences of chronically blocking a peptide that does much more than cause headaches. The cardiovascular safety profile of long-term CGRP inhibition is an active area of research and post-market surveillance.

Isolated atrial tissue in a dish does not replicate the full complexity of a beating heart in a living person — compensatory mechanisms, autonomic nervous system regulation, and drug metabolism are absent. The tissue came from cardiac surgery patients who may not represent the typical migraine patient population. Whether reduced atrial contraction force at these concentrations has any clinical significance in living patients remains unknown.